TWI756299B - Magl抑制劑 - Google Patents

Magl抑制劑 Download PDF

Info

Publication number
TWI756299B
TWI756299B TW106139775A TW106139775A TWI756299B TW I756299 B TWI756299 B TW I756299B TW 106139775 A TW106139775 A TW 106139775A TW 106139775 A TW106139775 A TW 106139775A TW I756299 B TWI756299 B TW I756299B
Authority
TW
Taiwan
Prior art keywords
pharmaceutically acceptable
compound
formula
solvate
acceptable salt
Prior art date
Application number
TW106139775A
Other languages
English (en)
Chinese (zh)
Other versions
TW201823216A (zh
Inventor
雪瑞兒 A 葛莉絲
丹尼爾 J 布澤德
麥可 B 賽格哈菲
Original Assignee
丹麥商Ｈ 朗德貝克公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 丹麥商Ｈ 朗德貝克公司 filed Critical 丹麥商Ｈ 朗德貝克公司
Publication of TW201823216A publication Critical patent/TW201823216A/zh
Application granted granted Critical
Publication of TWI756299B publication Critical patent/TWI756299B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/195—Radicals derived from nitrogen analogues of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW106139775A 2016-11-16 2017-11-16 Magl抑制劑 TWI756299B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662423099P 2016-11-16 2016-11-16
US62/423,099 2016-11-16

Publications (2)

Publication Number Publication Date
TW201823216A TW201823216A (zh) 2018-07-01
TWI756299B true TWI756299B (zh) 2022-03-01

Family

ID=62106678

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106139775A TWI756299B (zh) 2016-11-16 2017-11-16 Magl抑制劑

Country Status (29)

Country Link
US (1) US10093635B2 (https=)
EP (1) EP3541821A4 (https=)
JP (1) JP7042547B2 (https=)
KR (1) KR20190077544A (https=)
CN (1) CN110267963B (https=)
AR (1) AR110089A1 (https=)
AU (1) AU2017361251B2 (https=)
BR (1) BR112019009994A2 (https=)
CA (1) CA3043615A1 (https=)
CL (1) CL2019001339A1 (https=)
CO (1) CO2019005059A2 (https=)
CR (1) CR20190241A (https=)
DO (1) DOP2019000122A (https=)
EA (1) EA038090B1 (https=)
EC (1) ECSP19035077A (https=)
GE (2) GEP20237470B (https=)
IL (1) IL266523B (https=)
JO (1) JOP20190106A1 (https=)
MA (1) MA46857A (https=)
MX (1) MX391117B (https=)
NI (1) NI201900051A (https=)
PE (1) PE20191144A1 (https=)
PH (1) PH12019501097A1 (https=)
RU (1) RU2754536C1 (https=)
TN (1) TN2019000153A1 (https=)
TW (1) TWI756299B (https=)
UA (1) UA124542C2 (https=)
WO (1) WO2018093947A1 (https=)
ZA (1) ZA201903100B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141702A1 (es) 2012-01-06 2014-11-19 Abide Therapeutics Inc Compuestos de carbamato y preparacion y uso de los mismos
CN113413387A (zh) 2015-05-11 2021-09-21 H.隆德贝克有限公司 治疗炎症或神经性疼痛的方法
US10899737B2 (en) 2016-09-19 2021-01-26 Lundbeck La Jolla Research Center, Inc. Piperazine carbamates and methods of making and using same
UA124884C2 (uk) 2016-11-16 2021-12-08 Лундбек Ла Джолла Ресеарч Центер, Інк. Фармацевтичні склади
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
MA46866B1 (fr) 2016-11-16 2021-11-30 H Lundbeck As Une forme cristalline d'un inhibiteur de magl
DK3630744T3 (da) 2017-05-23 2023-03-06 H Lundbeck As Pyrazol-magl-inhibitorer
JP7257387B2 (ja) 2017-08-29 2023-04-13 ハー・ルンドベック・アクチエゼルスカベット スピロ環化合物並びにその作製及び使用方法
GEP20227443B (en) * 2018-05-15 2022-11-25 H Lundbeck As Magl inhibitors
CA3125636A1 (en) * 2019-01-25 2020-07-30 H. Lundbeck A/S Methods of treating disease with magl inhibitors
KR20220101095A (ko) * 2019-11-15 2022-07-19 하. 룬드벡 아크티에셀스카브 Magl 억제제의 결정형
IT202000007150A1 (it) * 2020-04-03 2021-10-03 Univ Pisa Inibitori di monoacilglicerolo lipasi (magl)
WO2021214550A1 (en) 2020-04-21 2021-10-28 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
KR20250005229A (ko) 2022-05-04 2025-01-09 하. 룬드벡 아크티에셀스카브 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104159581A (zh) * 2012-01-06 2014-11-19 阿比德治疗公司 氨基甲酸酯化合物及其制备和使用方法
WO2016149401A2 (en) * 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1593586A (https=) 1967-10-17 1970-06-01
JPS6183073A (ja) 1984-10-01 1986-04-26 Oki Electric Ind Co Ltd 印字装置の用紙送り方法
WO1989011794A1 (fr) 1988-06-07 1989-12-14 Rikagaku Kenkyusho Inhibiteur de la croissance de plantes
EP0619804B1 (en) 1991-11-27 1996-05-22 E.I. Du Pont De Nemours And Company Herbicidal acylated amino-(phenyl- or pyridinyl- or thienyl-)-phenyl derivatives
DE69408873T2 (de) 1993-12-22 1998-07-09 Shell Int Research Verfahren zur herstellung von carbamaten
WO1997018196A1 (en) 1995-11-15 1997-05-22 Zeneca Limited Herbicidal substituted pyrazole compounds
AU3440597A (en) 1996-07-02 1998-01-21 Novartis Ag N-phenylimino heterocyclic derivatives and their use as herbicides
RU2167150C2 (ru) 1998-03-25 2001-05-20 Фокин Александр Васильевич Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью
AU7855900A (en) 1999-10-04 2001-05-10 University Of Medicine And Dentistry Of New Jersey Methods for identifying rna binding compounds
EP1201298A1 (en) 2000-10-24 2002-05-02 Urea Casale S.A. Carbamate condensation unit
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
FR2864080B1 (fr) 2003-12-23 2006-02-03 Sanofi Synthelabo Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
WO2005063698A1 (en) 2003-12-31 2005-07-14 Council Of Scientific & Industrial Research Process for preparing carbamates
BRPI0507499A (pt) 2004-02-18 2007-07-24 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável ou hidrato dos mesmos, composição farmacêutica, uso do composto, e, métodos para tratar distúrbios mediados por mglur 5 e para inibir a ativação de receptores de mglur 5
US7786113B2 (en) 2004-12-23 2010-08-31 Hoffman-La Roche Inc. Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents
AR055831A1 (es) 2004-12-30 2007-09-12 Janssen Pharmaceutica Nv Pepirazinilureas y piperidinilureas como moduladores de hidrolasa de amida de acidos grasos
WO2007052023A2 (en) 2005-11-05 2007-05-10 Astrazeneca Ab Novel compounds
JP2009523729A (ja) 2006-01-13 2009-06-25 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎の治療方法
WO2008078091A1 (en) 2006-12-22 2008-07-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
US7795457B2 (en) 2007-02-26 2010-09-14 Kosan Biosciences Incorporated Carbamate compounds
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
JP2011528368A (ja) 2008-07-16 2011-11-17 シェーリング コーポレイション 二環式ヘテロ環誘導体およびｇｐｃｒモジュレーターとしてのその使用
WO2010056309A2 (en) 2008-11-14 2010-05-20 The Scripps Research Institute Methods and compositions related to targeting monoacylglycerol lipase
WO2010111050A1 (en) 2009-03-23 2010-09-30 Banyu Pharmaceutical Co., Ltd. Novel aminopyridine derivatives having aurora a selective inhibitory action
US8455476B2 (en) 2009-04-22 2013-06-04 Janssen Pharmaceutica, Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
ES2433235T3 (es) 2009-11-03 2013-12-10 Bayer Intellectual Property Gmbh Fluorouretanos como aditivos en una formulación de fotopolímero
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
NZ627096A (en) 2012-01-06 2017-02-24 Agios Pharmaceuticals Inc Triazinyl compounds and their methods of use
CA2866302A1 (en) 2012-03-19 2013-09-26 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
JP2014005245A (ja) 2012-06-26 2014-01-16 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体を含有する医薬組成物
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
JP6647592B2 (ja) * 2013-07-03 2020-02-14 ルンドベック ラ ホーヤ リサーチ センター，インク． ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用
US10570146B2 (en) * 2014-07-25 2020-02-25 Northeastern University Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof
US10899737B2 (en) 2016-09-19 2021-01-26 Lundbeck La Jolla Research Center, Inc. Piperazine carbamates and methods of making and using same
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104159581A (zh) * 2012-01-06 2014-11-19 阿比德治疗公司 氨基甲酸酯化合物及其制备和使用方法
WO2016149401A2 (en) * 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same

Also Published As

Publication number Publication date
BR112019009994A2 (pt) 2019-08-27
IL266523B (en) 2022-09-01
NI201900051A (es) 2019-10-30
CL2019001339A1 (es) 2019-10-04
KR20190077544A (ko) 2019-07-03
AU2017361251B2 (en) 2021-08-19
CN110267963B (zh) 2022-04-01
GEAP202215088A (en) 2022-08-25
PE20191144A1 (es) 2019-09-02
MX2019005776A (es) 2019-12-05
MX391117B (es) 2025-03-21
US20180134674A1 (en) 2018-05-17
TW201823216A (zh) 2018-07-01
ZA201903100B (en) 2020-11-25
ECSP19035077A (es) 2019-05-31
AU2017361251A1 (en) 2019-05-30
AR110089A1 (es) 2019-02-20
US10093635B2 (en) 2018-10-09
CR20190241A (es) 2019-09-02
TN2019000153A1 (en) 2020-10-05
GEP20237470B (en) 2023-02-10
CN110267963A (zh) 2019-09-20
PH12019501097A1 (en) 2019-08-19
DOP2019000122A (es) 2019-09-30
MA46857A (fr) 2019-09-25
CO2019005059A2 (es) 2019-05-31
EA038090B1 (ru) 2021-07-05
RU2754536C1 (ru) 2021-09-03
EP3541821A1 (en) 2019-09-25
CA3043615A1 (en) 2018-05-24
JOP20190106A1 (ar) 2019-05-09
RU2019116512A (ru) 2020-12-17
UA124542C2 (uk) 2021-10-05
EP3541821A4 (en) 2020-04-22
WO2018093947A1 (en) 2018-05-24
IL266523A (en) 2019-07-31
NZ753264A (en) 2020-12-18
JP7042547B2 (ja) 2022-03-28
EA201991073A1 (ru) 2019-12-30
JP2020504707A (ja) 2020-02-13

Similar Documents

Publication Publication Date Title
TWI756299B (zh) Magl抑制劑
US11214557B2 (en) MAGL inhibitors
US11059822B2 (en) MAGL inhibitors
CN110248947B (zh) Magl抑制剂
TWI874919B (zh) 雙重magl及faah抑制劑
NZ753264B2 (en) Magl inhibitors

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees